Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Depot Buprenorphine (RBP-6000) in Opioid-Dependent Subjects

X
Trial Profile

A Multicenter, Open-Label, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Depot Buprenorphine (RBP-6000) in Opioid-Dependent Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Opioid-related disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Indivior
  • Most Recent Events

    • 22 Feb 2019 Results assessing the effects of a monthly buprenorphine depot subcutaneous injection on QT interval during treatment for opioid use disorder in 1114 subjects pooled from 5 studies (RB-US13-0001, RB-US10-0011, RB-US11-0020, RB-US12-0005, RB-US13-0006) published in the Clinical Pharmacology and Therapeutics
    • 29 Dec 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top